surgery Archives

News and Trends 31 Mar 2023

Destiny Pharma gel reduces nasal staph in surgery patients

Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […]

March 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Stem cell plasters could revolutionize heart surgeries

Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […]

December 21, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Novadip bone healing trial yields positive results

Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003. The study was on patients with severe bone non-union (BNU) of the lower limb following trauma. Novadip is a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to […]

December 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Biocomposites antibiotic carrier, STIMULAN, receives approval for use in Mexico

UK-based medical devices company, Biocomposites Ltd., has announced that antibiotic carrier STIMULAN has received a new broad-based approval for use in bone and soft tissue in Mexico. The approval, granted by COFEPRIS, the Mexican Regulatory Authority, authorizes the use of STIMULAN as a carrier of substances such as antibiotics that are chosen by the surgeon […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

MedinCell’s partner AIC registers trial for drug for total knee replacement pain

A partner of MedinCell, Arthritis Innovation Corporation (AIC), has registered a phase 3 trial to look into an alternative drug to deal with pain after total knee replacement (TKR). Arthritis Innovation Corporation conducts and finances all development activities of the drug F14, or mdc-CWM, being trialed. It was registered with the safety and efficacy study […]

November 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Oct 2022

New biotech company aims to bridge gap between stem cell research and athletic injuries

Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of Andrews Celltex Biologics. The new company will undertake the operation of […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 26 Sep 2022

Surge raises $2.6M in funding for technology and secures exclusive licensing agreement

Surge, a biotech and artificial intelligence innovator that produces technology to decode immune fingerprints, has received $2.6 million in funding. The technology accurately identifies patients at risk before surgery and enables physicians to quickly forecast the risk of postoperative complications. The funding round was co-led by HCVC, a global early-stage fund dedicated to high-potential […]

September 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

FDA approves Heron Therapeutics’ post-op nausea and vomiting drug

Heron Therapeutics, Inc. says the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. Heron Therapeutics’ APONVIE is the first and only IV formulation of aprepitant for PONV prevention. Administered via a single 30-second IV injection, APONVIE reaches […]

September 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Sep 2022

Results of phase 3 trial of injection for ovarian cancer imaging published

An injection for intraoperative imaging of folate receptor positive ovarian cancer can identify more of the disease than is unable to be identified conventionally. Biotech company On Target Laboratories announced that the results from its phase 3, 006 study of the Cytalux (pafolacianine) injection had been published in the Journal of Clinical Oncology yesterday (September […]

September 13, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us